Observational Study of Ravulizumab Treatment in Adults With Generalized Myasthenia Gravis Not Previously Treated with Complement Inhibitors in Poland

What this Trial Is About

This research aims to collect detailed information on how patients with generalized myasthenia gravis gMG who have not previously received complement inhibitor treatments manage their condition while being treated with ravulizumab. The study is conducted across multiple centers in Poland and observes patients receiving this treatment as part of routine clinical practice within the National Drug Program. Participants receive ravulizumab, a drug given as an infusion, and are followed for up to 42 months. This includes approximately 6 months of initial baseline observation and about 36 months of follow-up to track their progress and treatment effects. The study does not intervene but collects data on treatment management and outcomes over this period. During the study, participants will undergo assessments measuring their daily living activities related to myasthenia gravis using the MG-ADL score, along with other evaluations such as quality of life, fatigue, mood, and work productivity at various intervals up to 36 months. These help researchers understand changes in health and function over time. Safety and clinical outcomes are monitored throughout, with the study sponsored by AstraZeneca and expected to continue until the end of 2029.

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis